Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Late stage melanoma treatment presentation at healthcare conference

Immunocore : 14 January, 2014  (Company News)
Immunocore will be present at the JP Morgan Healthcare conference to discuss the treatment of late stage melanoma
Late stage melanoma treatment presentation at healthcare conference


Immunocore, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, will present at the 32nd annual JP Morgan Healthcare Conference on Thursday 16 January 2014 at 11:30 am (Pacific Time) at the Westin St Francis Hotel, San Francisco.



James Noble, Chief Executive Officer, will present a corporate update and data from Immunocore’s most advanced ImmTAC programme, IMCgp100, for the treatment of late stage melanoma. Phase I testing was completed in late 2013, with promising early signs of efficacy indicated, and the company has initiated a Phase IIa trial in the UK and USA designed to optimize the dosing regimen and maximise the efficacy of IMCgp100.



Last week Immunocore announced its third partnership deal in six months - an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s ImmTAC technology.



Immunocore’s novel bi-specific biologics platform exploits the power of the body’s own immune system to find and kill diseased cells. ImmTACs direct a patient’s T cells to specifically destroy only the cancerous cells, avoiding damage to healthy cells.



Immunocore also has major discovery collaborations ongoing with leading pharmaceutical companies Genentech and GlaxoSmithKline.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo